Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery

Abstract This study presents a novel approach targeting CD155, an overexpressed protein in lung adenocarcinoma (LUAD), using nanobodies with exceptional precision and efficacy. The significant upregulation of CD155 in LUAD, associated with poor patient outcomes, highlights its potential as a therape...

Description complète

Détails bibliographiques

Auteurs principaux:	Kyunghee Noh, Soyeon Yi, Hyeran Kim, Jieun Lee, Suhyeon Kim, Wonbeak Yoo, Eunkyeong Jung, Jinsol Choi, Hwangseo Park, Seungha Hwang, Jin Young Kang, Kwang-Hyun Park, Heewon Park, Yong-kyu Lee, Eun-Kyung Lim, Taejoon Kang, Juyeon Jung
Format:	Artigo
Langue:	Inglês
Publié:	Nature Publishing Group 2025-07-01
Collection:	Signal Transduction and Targeted Therapy
Accès en ligne:	https://doi.org/10.1038/s41392-025-02301-z
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!